Key Points - Vanke A has signed a supplementary agreement with Shenzhen Metro Group for a loan of up to 4.2 billion yuan, with a pledge of up to 6 billion yuan in shares of its subsidiary, Wanwu Cloud [3] - Heng Rui Pharmaceutical has set the final price for its H-share issuance at 44.05 HKD per share, with plans to list on the Hong Kong Stock Exchange on May 23, 2025 [4] - Wan Dong Medical has elected Ma Chibing as the new chairman after Hu Ziqiang resigned from the position [5] - Tianqi Mould has confirmed that there are no undisclosed significant matters amid ongoing major asset restructuring [6] - Zhejiang Rongtai plans to invest 20 million yuan to establish a wholly-owned subsidiary focused on intelligent robotics [7] - ST Mingcheng intends to publicly transfer 45% of its subsidiary, Time Media, which will no longer be included in the consolidated financial statements [8] - Shanghai Xiba plans to purchase patent assets for 2 million yuan and 500,000 yuan, and establish subsidiaries to promote the commercialization of new technologies [9] - Jushen Co. has received a total of 95.7 million yuan in dividends from its six wholly-owned subsidiaries [10] - ST Asia Pacific has confirmed no undisclosed significant matters or ongoing major plans [11] - Tianrong Tianyu's controlling shareholder's agreement will not be renewed after its expiration [12] - Wangzi New Materials has stated that its energy storage capacitor business is minimal and will not significantly impact its performance [13] - Nanjing Port has clarified that its foreign trade container business does not have direct routes to the U.S. [14] - Jinlongyu has indicated that its solid-state battery business has not yet formed stable long-term revenue [15] - Tianzhihang's subsidiary plans to raise capital by introducing investors [16] - State Grid Information plans to acquire 100% of Yili Technology for 1.853 billion yuan, enhancing its revenue and profit [17] - ST Nongsang will remove its delisting risk warning starting May 23 [18] - Yipin Hong has stated that its innovative drug AR882 has not yet been launched and will not significantly impact recent performance [19] - Huanrui Century has announced a performance compensation plan requiring original shareholders to compensate 116 million shares [20] - Huaren Health plans to acquire stakes in three pharmaceutical chain companies for a total of 3.282 billion yuan [21][22] - Hongming Co. is planning to acquire 83% of Shenzhen Chisu for 1.51 billion yuan [23] - Aishida intends to acquire an additional 7% stake in its subsidiary Qianjiang Robot for 13.09 million yuan [24] - Dasheng Intelligent has signed a contract worth 11.5 million yuan for a high-efficiency machine room project [25] - Jinggu Co. has received a notice to supply wheels for a major global automaker, with expected sales of approximately 158 million USD over ten years [26] - Pingzhi Information has signed a framework agreement with China Mobile for antenna products worth up to 13.01 million yuan [27] - Shanghai Laishi's controlling shareholder plans to increase its stake by 250 million to 500 million yuan [28] - Qixia Construction's shareholder plans to reduce its stake by up to 3% [29] - Sichuan Gold's major shareholders plan to reduce their stakes by up to 5.5% [30] - Qingyun Technology's shareholders plan to reduce their stakes by up to 4.5% [31] - Rhein Biological's directors plan to reduce their stakes by up to 0.14% [32] - Qingmu Technology's shareholder plans to reduce its stake by up to 3% [33] - Sanrenxing's employee shareholding platform plans to reduce its stake by up to 3% [34][35] - Juzhi Technology's director plans to reduce his stake by up to 40,000 shares [36] - Jingwang Electronics' major shareholders plan to reduce their stakes by up to 2.99% [37] - Jujiao Co. plans to reduce its stake by up to 2.6% [38] - Xiyu Tourism's major shareholder plans to reduce its stake by up to 3% [39]

Core Viewpoint - Shanghai Xiba plans to acquire patents and establish two holding subsidiaries to promote the industrialization of high-energy hydrogen-electric hybrid power systems and special solid-state lithium-ion battery technologies, enhancing its position in the new energy sector [1][2]. Summary by Sections Patent Acquisition - Shanghai Xiba will purchase four invention patents and one utility model patent from the Dalian Institute of Chemical Physics, Chinese Academy of Sciences, for a total of 25 million yuan (approximately 3.5 million USD) [1]. Subsidiary Establishment - The company intends to set up two holding subsidiaries with a registered capital of 10 million yuan (approximately 1.4 million USD) each, in collaboration with its core technology and management teams [1][2]. Business Strategy - The establishment of these subsidiaries aligns with the company's business and strategic planning, aiming to integrate technical advantages and resources from partners to enhance its capabilities and competitiveness in the new energy sector [2]. Current Business Context - Shanghai Xiba's main business involves customized water treatment chemicals and equipment, with a recent focus on advanced materials for solid-state batteries [3]. The company has completed the design of high-energy soft-pack lithium-ion solid-state batteries, which are now in small-scale production [3]. Financial Performance - In Q1 2025, the company reported a significant decline in net profit by 51% year-on-year to 9.83 million yuan (approximately 1.4 million USD), with a 17% drop in revenue, primarily due to the lack of high-margin projects compared to the previous year [4]. Future Outlook - Despite substantial investments in advanced materials, the business has not yet generated stable, large-scale revenue [5]. The company plans to focus on its core water treatment services while gradually reducing its involvement in engineering construction, aiming to develop a second growth curve in the new energy advanced materials sector [4].

Group 1 - Huiyu Pharmaceutical's subsidiary received drug registration certificate for Carboxymethyl Sodium Injection, which is used for treating bleeding diseases in various medical fields [1] - Baihe Co., Ltd. announced a plan for a director to reduce holdings by up to 424,000 shares, representing 0.6625% of the total share capital [1] - Kingood Co., Ltd. received a notification from a global leading automaker for a wheel project, expected to start mass production in 2026 with a lifecycle of 10 years [1][2] Group 2 - Wanhua Chemical plans to repurchase shares worth between 300 million and 500 million yuan, with a maximum repurchase price of 99.36 yuan per share [2] - Warner Pharmaceutical's subsidiary received approval for Acetylcysteine raw material drug, primarily used for treating respiratory diseases [3] - ST Mingcheng plans to publicly transfer 45% equity of its subsidiary, aiming to optimize asset structure [4] Group 3 - Qixia Construction announced a plan to reduce up to 31.5 million shares, accounting for 3% of total share capital [5][6] - Zhejiang Rongtai intends to invest 20 million yuan to establish a wholly-owned subsidiary focused on intelligent robotics [7] - Yuandong Biological received drug registration for Chloral Hydrate Enema, used for sedation and seizure control in children [9] Group 4 - Jiemai Technology's subsidiary signed a strategic cooperation agreement with a solid-state battery company to produce high-safety composite conductive materials [10] - Xianju Pharmaceutical received drug registration for Progesterone Soft Capsules, used for treating functional disorders due to luteal deficiency [11] - Lanhua Kecai's subsidiary reported a temporary production halt, with the resumption date yet to be determined [13] Group 5 - Sinopharm Modern's subsidiary received drug registration for Tocilizumab Tablets, used for treating rheumatoid arthritis and other conditions [15] - Shanghai Bank announced the resignation of its vice president due to organizational adjustments [17] - Shanghai Pharmaceutical's Ephedrine Injection passed the consistency evaluation for generic drugs [19] Group 6 - Rundu Co., Ltd. received drug registration for Amlodipine and Olmesartan Tablets, aimed at treating hypertension [21] - Zhong'an Technology announced that 61 million shares held by its controlling shareholder will be auctioned [23] - Shanghai Washba plans to purchase patent assets and establish two subsidiaries focused on hydrogen energy and solid-state battery technologies [25] Group 7 - Nuo Cheng Jianhua's new drug Tafasitamab received approval for treating relapsed/refractory diffuse large B-cell lymphoma [26] - Benli Technology plans to use up to 200 million yuan of idle funds for cash management and financial investments [28] - Taiji Co., Ltd. intends to use 60 million yuan of idle funds to purchase financial products [29] Group 8 - Haishi Co. announced that its innovative drug Anreke Fen Injection received drug registration for treating postoperative pain [32] - Yulong Co. will have its stock delisted on May 27, 2025, following a decision by the Shanghai Stock Exchange [36] - Weifu High-Tech plans to establish a joint venture with Shanghai Baolong Automotive Technology [38] Group 9 - Xichang Electric Power expects a net profit reduction of approximately 5.4 million yuan due to adjustments in the time-of-use electricity pricing mechanism [39] - Alter signed a contract worth 6.8 billion yen for the development and procurement of large truck EV kits [41] - Zhonglian Heavy Industry plans to acquire controlling stakes in its financing leasing subsidiary through public bidding [42] Group 10 - Sanyou Medical's executive plans to reduce holdings by up to 1.44% of the company's shares [43] - Hangyang Co. plans to establish a subsidiary for large modular cryogenic equipment manufacturing with an estimated investment of 557 million yuan [44] - FAW Fuwi received a notification for a dashboard project from a well-known new energy brand, with total sales expected to reach 1.06 billion yuan [45]

证券代码：603200 证券简称：上海洗霸 公告编号：2025-026 上海洗霸科技股份有限公司 关于购买专利资产 及对外投资设立控股子公司的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 重要内容提示： 上海洗霸科技股份有限公司（以下简称"公司"）与中国科学 院大连化学物理研究所拟签订《高比能氢电混动电源系统技术转让 （专利权）合同》，约定以人民币 2,000 万元购买 3 项发明专利和 1 项实用新型专利的专利权；拟签订《特种固态锂离子电池技术技术 转让（专利权）合同》，约定以人民币 500 万元购买 2 项发明专利的 专利权。 为推动前述高比能氢电混动电源系统和特种固态锂离子电池 技术的产业化发展，公司拟分别与相关核心技术团队、管理团队合 资设立公司控股的子公司，注册资本均为 1,000 万元人民币。 本次交易事项不属于关联交易，也不构成重大资产重组。 相关风险提示：结合国内外相关市场的竞争形势，随着新能 源领域相关技术的不断革新和新生产工艺的出现，上述技术在产业 化、客户认可、市场竞争、技术替代等方面均面临不确 ...

Group 1 - The company Shanghai Xiba plans to acquire the patent rights for three invention patents and one utility model patent from the Dalian Institute of Chemical Physics, Chinese Academy of Sciences for 20 million yuan [1] - Additionally, the company intends to purchase the patent rights for two invention patents for 5 million yuan [1] - The company plans to establish two holding subsidiaries with a registered capital of 10 million yuan each in partnership with its core technology and management teams to promote the industrialization of related technologies [1] Group 2 - The transactions do not constitute related party transactions or major asset restructuring [1]

Group 1 - The A-share solid-state battery sector experienced a short-term surge, with Guoxuan High-Tech hitting the daily limit [1] - Binhai Energy, Ningxin New Materials, and Jinlongyu previously reached their daily limit, indicating strong market interest [1] - Lingge Technology and Lingpai Technology saw increases of over 10%, reflecting positive sentiment in the sector [1] Group 2 - Other companies such as Honggong Technology, Shanghai Xiba, Manns Technology, Mengguli, and Liyuanheng also experienced gains, showcasing a broader rally in the industry [1]

A股固态电池概念局部冲高，金龙羽直线涨停，成交额超1亿元；国轩高科涨近7%，上海洗霸、德尔股 份跟涨。 ...

Core Viewpoint - The solid-state battery concept stocks experienced a significant surge, with Jinlongyu hitting the daily limit, driven by positive developments in the industry and announcements from Guoxuan High-Tech [1] Group 1: Stock Performance - Jinlongyu saw a limit-up in its stock price during the afternoon session [1] - Guoxuan High-Tech, Lingpai Technology, Wanrun New Energy, and Lingge Technology all rose over 5% [1] - Other companies such as Shanghai Washba, Better Ray, and Zhenhua New Materials also experienced gains [1] Group 2: Industry Developments - Guoxuan High-Tech held the 2025 Global Technology Conference, where it announced the completion of a 0.2 GWh pilot line for solid-state batteries [1] - The company introduced six new products, including the G-Yuan quasi-solid-state battery [1] - The quasi-solid-state battery has already been tested by more than four customers [1]

Core Viewpoint - Shanghai Xiba Technology Co., Ltd. plans to return the land use rights of a specific plot due to adverse external economic conditions, industry environment, and cash flow pressures, aiming to mitigate potential risks and losses [4][5][9]. Group 1: Meeting Details - The first extraordinary general meeting of shareholders for 2025 is scheduled for May 26, 2025, at 14:30, located at 1230 Zhongshan North Road, Shanghai [1][2]. - The meeting will utilize a combination of on-site and online voting methods, allowing shareholders to exercise their voting rights through the Shanghai Stock Exchange's online voting system [2][3]. Group 2: Proposal for Land Use Rights Return - The proposal involves the return of land use rights for a plot in Jiading District, which was initially acquired for the construction of the Shanghai Xiba Environmental Technology Industrial Park [4][5]. - The land area is 8,867 square meters, with a transaction amount of 127.69 million yuan [4]. - Due to various factors, including the COVID-19 pandemic and unfavorable market conditions, the project has not progressed as expected, leading to significant cash flow pressure on the company [5][6]. Group 3: Financial Implications - The return of the land use rights is expected to result in an estimated loss of approximately 36.42 million yuan, which represents about 85% of the company's audited net profit for the previous year [9][10]. - The loss includes direct land costs of 29.43 million yuan and design, surveying, and construction costs of 6.99 million yuan [10]. - The company anticipates that this decision will not affect its normal operations and is aimed at safeguarding overall corporate interests and ensuring stable development [9][11].

会议资料 上海洗霸科技股份有限公司董事会 二〇二五年五月二十六日 上海洗霸科技股份有限公司 （上海市虹口区中山北一路 1230 号柏树大厦 B 区 5 楼） 2025 年第一次临时股东大会 上海洗霸科技股份有限公司 2025 年第一次临时股东大会会议资料 上海洗霸科技股份有限公司 2025 年第一次临时股东大会文件 目录 | 2025 | 年第一次临时股东大会与会须知 | 2 | | --- | --- | --- | | 2025 | 年第一次临时股东大会议程 | 3 | | 2025 | 年第一次临时股东大会议案 | 4 | | | 议案 1：关于全资子公司退回土地使用权的议案 | 4 | 第1页 上海洗霸科技股份有限公司 2025 年第一次临时股东大会会议资料 上海洗霸科技股份有限公司 2025 年第一次临时股东大会与会须知 各位股东/股东代表（以下简称股东）： 为确保上海洗霸科技股份有限公司（以下简称公司）2025 年第一次临时股 东大会（以下简称本次大会）顺利进行，根据《中华人民共和国公司法》《上市 公司股东大会规则》《上市公司股东大会网络投票实施细则》及公司《章程》《股 东大会议事规则》的规定，制 ...